Bionano Genomics, Inc.

Good day and welcome to the BioNano Genomics third quarter 2021 earnings conference call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Amy Conrad from Investor Relations. Please go ahead.

Thank you, Michelle. And good afternoon, everyone.

Welcome to the BioNano Genomics third quarter 2021 financial results conference call. Leading the call today is Dr. Eric Holmland, CEO of BioNano. He is joined by Chris Stewart, CFO of BioNano, and Rich Shippey, CBO of BioNano. After market closed today, BioNano issued a press release announcing its financial results for the third quarter of 2021. A copy of the release can be found on the investor relations page of the company's website. I would like to remind everyone that certain statements made during this conference call may be forward-looking, including statements about BioNano's strategic and commercialization plans, sales pipeline, anticipated benefits or improvements to the Sapphire system, anticipated milestones for 2021, and the advantages of the SAFIRE system over current technologies, the anticipated benefits of the acquisition of biodiscovery, our expectations regarding timing and content of study results, and anticipated benefits of these studies in driving adoption of the SAFIRE system. Such forward-looking statements are based upon current expectations and there can be no assurances that the results contemplated in these statements will be realized. Actual results may differ materially from set statements due to a number of factors and risks, some of which are identified in BioNano's press release and BioNano's reports filed with the SEC. These forward-looking statements are based on information available to BioNano today, and the company assumes no obligation to update statements as circumstances change. An audio recording and webcast replay for today's conference call will also be available online in the Investors section of the company's website.